Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)
暂无分享，去创建一个
V. Seshan | A. Zelenetz | O. Abdel-Wahab | A. Dogan | J. Abramson | M. Matasar | Anita Kumar | Puja Chadha | L. Falchi | Caleb Ho | J. Soumerai | C. Owens | C. Batlevi | A. Joseph | N. Khan | P. Johnson | Colette N Owens | K. Flaherty | Chaya Friedman | Elizabeth Simkins | Jade Ruiters | Sidney Sechio | R. Martignetti | Joanna Mi | Clare Grieve | C. Friedman | A. Dogan